Podcasts about metastatic

Artificial Intelligence is buzzy. There's a lot about it in the news and a lot we think we understand about how to use it and a lot we may not fully understand. But the promise it holds is tremendous, and today we're going to learn a little more about how it could benefit breast cancer research and patient care in the near future. Drs. Charles Perou at UNC Chapel Hill and Erika Crosby at Duke University are two very accomplished breast cancer researchers who are joining us today to share their perspectives on using AI now and in the future. Key takeaways AI is improving breast cancer screening and diagnosis. Researchers are using AI to save time on coding, writing, and data analysis. AI can help match patients to clinical trials more effectively. Human expertise is still needed to verify AI-generated results. AI has the potential to accelerate research and improve patient care. Chapters 00:00 — Introduction to AI in Breast Cancer Research 02:53 — Ethical Considerations and Responsible AI Use 04:33 — Current Clinical Applications of AI 08:12 — How Researchers Are Using AI in the Lab 11:17 — AI Limitations, Mistakes, and Critical Thinking 17:23 — The Future of AI-Assisted Cancer Research Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

We know that clinical trials are a critical lifeline, offering new ways to prevent, detect, diagnose and treat breast cancer. Today, patient advocates are transforming clinical trials by bringing the real-world experiences of patients directly to researchers. By acting as a bridge between science and the community, patient advocates boost enrollment in clinical trials, and help build a lasting trust Today we are speaking with Dr. Lior Braunstein, a radiation oncologist and researcher at Memorial Sloan Kettering Cancer Center, and Dr. Ellen Landsberger, a retired OB-GYN and patient advocate, also at Memorial Sloan Kettering Cancer Center. Together they are working on the ARCHER clinical trial, a study that is investigating a new treatment strategy for HER2-positive metastatic breast cancer. We'll talk about what they are hoping to accomplish through the ARCHER trial, what their collaborative process looks like and how patient advocates in clinical trials can help improve patient outcomes. Key Takeaways: Patient advocates help design better clinical trials The ARCHER trial aims to improve treatment outcomes Patient voices shape research from the very beginning Clinical trials study both treatment and quality of life Better access helps more patients join clinical trials Chapters 00:00:00 – Why patient advocates belong at the clinical trial design table 00:04:44 – From breast cancer survivor to patient advocate 00:07:46 – How advocates shape research and address patient concerns 00:12:08 – Inside the ARCHER trial and its goal to improve metastatic breast cancer treatment 00:19:03 – Measuring quality of life and improving access to clinical trials 00:26:28 – How patients can become advocates and influence future research

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

At just 32 years old, Keisha Kinison was working in women's health when she suddenly found herself as the patient. In this episode, we'll talk about what it was like to discover her diagnosis before a physician had the chance to call, why she made the difficult decision to change doctors during treatment, how her experience transformed her and the incredible support that helped carry her through. Woven throughout every chapter of her story is one powerful message: trust yourself, advocate for yourself, and never be afraid to seek the care you deserve. Key takeaways: Breast cancer can happen at a young age Self-advocacy is essential A strong support system makes a difference Treatment can involve unexpected setbacks Know your body and don't ignore changes Chapters 00:00 Keisha's breast cancer diagnosis at age 32 01:52 Testing, imaging, and receiving the diagnosis 05:12 Triple-negative breast cancer and treatment challenges 09:15 Advocating for herself and changing oncologists 12:11 The support that carried her through treatment 15:33 How cancer changed her career and advice for others Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Send us Fan Mail

Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.

There is a lot of conversation right now about funding for cancer research and possible cuts to research projects that will improve our understanding and treatment of breast cancer. I'm pleased to be joined today by two researchers who are sharing their perspectives on the inextricable link between grant funding and sustained research. Dr. Benjamin Schrank is an Assistant Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and Dr. Donald McDonnell is the Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology at Duke University School of Medicine. Dr. McDonnell is a well-established researcher whose work focuses on developing new drugs to treat metastatic breast cancer. Dr. Schrank is early in his research career and focused on harnessing the body's immune system to improve response to treatments for metastatic breast cancer. Both recently received research grants from Susan G. Komen to support their innovative work that will help improve breast cancer care and patient outcomes. Key Takeaways: Breakthrough cancer treatments can take decades to develop Fundamental research is the foundation of future therapies Early-stage funding is critical for innovation Research funding directly impacts patients Chapters 00:00 Introduction 01:40 Meet the researchers and their current projects 03:45 Why medical breakthroughs take decades to achieve 11:15 The critical role of grant funding in scientific research 20:20 Supporting the next generation of cancer researchers Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We're Heading (0:00) First-Line Treatment of BRCA Wild-Type Disease (9:14) First-Line Treatment of BRCA-Mutant Disease (38:48) Novel Approaches (47:49) CME information and select publications

Welcome to the Komen Health Equity Revolution series on Real Pink — where patients, advocates, researchers and community partners come together to talk honestly about what's standing in the way of breast health equity, and what we're doing to change it. June is Pride Month — a time to celebrate identity, community and the courage it takes to live authentically. Today's conversation sits right at the heart of that. Because advocating for yourself, knowing your body and refusing to be dismissed, that's not just a health message. That's a love letter to who you are. Our guest today is Shelby Smith. She was 30 years old when she noticed something felt off. No family history of breast cancer. Young, healthy, going about her life as a wife and mom to a 7-year-old daughter. But she trusted herself — and that decision changed everything. Shelby faced a 12-centimeter tumor, a bilateral mastectomy, 16 rounds of chemo and 15 rounds of radiation. She did her own research, built her own notebook, asked her own questions — and came out the other side with a message she wants every young woman to hear: Know your normal. And when something doesn't feel right, advocate for yourself. Key Takeaways: Trust your instincts when something feels off Self-advocacy can change outcomes Being informed helps patients navigate treatment Cancer can affect more than physical health Including loved ones in the journey matters Chapters 00:00 Introduction: Shelby's Breast Cancer Story 02:07 Discovering a Lump and Seeking Answers 04:37 Diagnosis, Testing, and Receiving the News 10:07 Research, Self-Advocacy, and Navigating Treatment 17:33 Identity, Family, and Talking to Her Daughter 24:46 Life After Treatment and Advice for Young Women Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

A breast cancer diagnosis may feel like it changes your entire life in an instant, but it doesn't get to define who you are or make all your choices for you. On today's episode of Real Pink, we're joined by Amanda Sangemino, a remarkable young woman whose diagnosis came at an age when cancer was likely the last thing on her mind. What began with a concern that was initially dismissed ultimately led her to trust her instincts, advocate for herself, and make a series of personal decisions about her treatment and future. Throughout the process, she was determined not to let fear and cancer make every decision for her. Today, she'll talk about the choices that she made about fertility, surgical options and maintaining an active lifestyle and why trusting yourself can be one of the most powerful tools you have. Key Takeaways: Mindset can play a powerful role during treatment Trust your instincts and advocate for yourself Maintaining normalcy can be empowering Don't let cancer make every decision for you A strong support system makes a difference Chapters: 00:00 – Amanda's Breast Cancer Story Begins 01:28 – Finding a Lump and Receiving a Misdiagnosis 04:22 – Seeking a Second Opinion and Getting Answers 07:00 – Why Self-Advocacy Matters for Young Women 10:00 – Fertility, Menopause, and Treatment Decisions 14:43 – Choosing Surgery, Staying Active, and Building Support 23:09 – Amanda's Final Advice Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Today on National Cancer Survivor's Day, we're joined by a remarkable performer whose strength, vulnerability, and resilience have inspired millions around the world. She has taken the stage as a backup vocalist for numerous top artists and most recently dazzled the crowds on the biggest tour in music history with global superstar Taylor Swift. However, audiences were moved even more deeply when she chose to publicly share something far more personal – her breast cancer journey. After Jeslyn Gorman's diagnosis become known through The Eras Tour docuseries, fans witnessed the emotional reality of navigating cancer while stepping away from a career and community she loves so deeply. From continuing to tour in the early days of diagnosis, to facing treatment side effects and returning to the stage immediately following treatment, her story is one of courage, grace and resilience. Today, Jeslyn opens up about the support she received, what survivorship looks like now and most importantly, shares an empowering message for young women about listening to their bodies, advocating for their health, and never underestimating the importance of early detection. Key Takeaways: Early detection can save lives. You can experience joy and fear at the same time. A strong support system makes a major difference. Recovery is gradual and requires patience. Cancer changes your life, but it doesn't define it. Chapters 00:00 – Jeslyn's Breast Cancer Diagnosis 05:24 – Continuing to Perform After Diagnosis 07:38 – Going Public With Her Cancer Story 13:22 – Breast Health and Self-Advocacy 18:07 – Support From Family, Friends, and the Tour Community 22:17 – Staying Positive During Treatment 25:17 – Chemotherapy and Physical Recovery 31:49 – Hair Loss and Identity Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship. 37:29 – Life After Treatment and Survivorship

This episode tells the story of how one man, Jake Messier, who is living with metastatic male breast cancer, is challenging the stigma surrounding this disease, which affects 1% of all breast cancer patients. It's an important reminder that not all cancers are funded and researched equally, and that behind every statistic is a person trying to live a normal life.Jake has used his lifelong PR skills to turn what is a diagnosis unlike any other into a conversation about equity, resilience and a deep societal stigma. This conversation should also serve as a reminder of how patients perceive the healthcare system and that communication is key when treating patients, many of whom are vulnerable.A huge thank you to Jake for coming on the show. If you want more information, see Jake's website: https://www.theguywithstage4breastcancer.com/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Has America abandoned the values that once shaped Western civilization? In this episode of 1819 News: The Podcast, host Bryan Dawson examines Pride Month, the rise of what he calls "Christless Conservatism," and the cultural forces he believes have transformed America over the last several decades. Bryan discusses the sexual revolution, the role of modern conservatism, the decline of traditional family values, and why he believes the Christian family remains the foundation of a healthy society. He also explains why many conservatives failed to resist cultural change and what Christians can do to reclaim their influence in the public square. Topics include: • Pride Month and modern cultural politics • The rise of Christless Conservatism • Faith, family, and Western civilization • The sexual revolution and its consequences • Christian responsibility in the culture war • Building strong families in a changing America Subscribe to 1819 News for more conversations on faith, culture, politics, and the issues shaping Alabama and the nation.

Has America abandoned the values that once shaped Western civilization? In this episode of 1819 News: The Podcast, host Bryan Dawson examines Pride Month, the rise of what he calls "Christless Conservatism," and the cultural forces he believes have transformed America over the last several decades. Bryan discusses the sexual revolution, the role of modern conservatism, the decline of traditional family values, and why he believes the Christian family remains the foundation of a healthy society. He also explains why many conservatives failed to resist cultural change and what Christians can do to reclaim their influence in the public square. Topics include: • Pride Month and modern cultural politics • The rise of Christless Conservatism • Faith, family, and Western civilization • The sexual revolution and its consequences • Christian responsibility in the culture war • Building strong families in a changing America Subscribe to 1819 News for more conversations on faith, culture, politics, and the issues shaping Alabama and the nation.

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

This episode originally aired in November 2023. When someone has metastatic breast cancer, it is scary for them - and for you! What can you do to really help? What should you say? Is it better to just listen? Today's guest received a de novo metastatic diagnosis in January 2021 and then elected to retire early from a 30-year technology sales career in order to slow life down and to focus on family, friends and thriving with MBC. Carlee Dixon's surprise diagnosis also inspired her to learn as much as possible about breast cancer and take every opportunity to educate friends and acquaintances about breast cancer prevention and the day to day reality. Today, Carlee is here to shed some light on how to best support those who are living with metastatic breast cancer.

In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article, "EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer" byTakahashi,  et al. LINK TO FULL TRANSCRIPT

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings

It's Women's Health Month — which means a lot of awareness messaging and a lot of conversation about why women's health matters. But today, we're going a level deeper. Because awareness doesn't save lives. Action does. Infrastructure does. Investment does. And honest conversations about why the system isn't working equally for everyone — those matter too. My guest today is Jenica Patterson — a neuroscientist turned health systems architect who is doing the hard work of figuring out why women's health is so chronically underinvested and what it will take to fix it. She leads the Women's Health Network at the Milken Institute, one of the most powerful cross-sector coalitions in this space. Before that, she built a $113 million federal program at ARPA-H (the Advanced Research Project Agency for Health) specifically designed to fast track innovation in women's health. Komen is focused on breast health access — and the sobering reality that where you live and what you look like still determine whether you get a timely mammogram, an accurate diagnosis or the best possible care. Jenica has the research, the relationships and the conviction to tell us exactly why that is — and what's possible. Key Takeaways: Women's health inequities are systemic, not individual. Nearly 30% of U.S. counties do not have a mammography machine. Women's health has historically been underrepresented in research and clinical development. Innovation alone is not enough without integration. Momentum in women's health is growing. Chapters 00:00 Jenica Patterson's journey from neuroscience to women's health systems leadership 05:45 Why women's health is at a major inflection point 08:40 The shocking mammography access gaps across the United States 14:02 Why solving women's health requires system-wide integration 20:03 Where momentum and hope are growing in women's health equity Learn more at realpink.komen.org and komen.org breastcancer #survivorship #womenshealth #cancersupport #realpink Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Menopause – it may be the most unwanted time in a woman's life. It arrives with a vengeance, forcing all kinds of emotional, hormonal and bodily changes onto women as they approach their 50s. But for women going through breast cancer treatment, it can arrive even earlier and be even more unwanted. The good news is no one has to suffer in silence. Today's guests are Dr. Makeba Williams, the incoming president of The Menopause Society, and Claudia McConnell, a breast cancer survivor who was forced into menopause during breast cancer treatment at age 37. Key takeaways Breast cancer treatment can trigger sudden and emotionally overwhelming early menopause Menopause symptoms after cancer treatment are real, serious, and treatable. Mental health support is a critical part of breast cancer survivorship care. Open conversations help reduce stigma and empower women to seek support. Chapters 00:00 Introduction to breast cancer and menopause realities 04:29 Claudia's breast cancer diagnosis and sudden menopause at 37 15:42 Why survivors shouldn't suffer through menopause symptoms alone 19:20 New menopause treatments and advances for breast cancer survivors 21:07 Sleep disruption, insomnia, and menopause management strategies 24:07 Estrogen creams, vaginal health, and treatment decision-making 30:19 BRCA2, talking to children about cancer risk, and family support 39:05 Final advice for women navigating menopause after breast cancer Learn more at realpink.komen.org and komen.org breastcancer #menopause #survivorship #womenshealth #cancersupport #realpink Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03) Key findings from the Phase III MAGNITUDE and TALAPRO-2 studies (15:10) Summary of efficacy data with PARP inhibitors; toxicities (20:01) Key findings and conclusions from the Phase III AMPLITUDE study; future directions with PARP inhibitors (23:33) CME information and select publications

Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surrounding toxicities associated with PARP inhibitors (15:25) Potential role of saruparib; evolving nomenclature in prostate cancer (22:36) Approach to newly diagnosed metastatic prostate cancer (26:16) Clinical relevance of PSMA-targeted PET imaging results (29:49) Case: A man in his mid 70s with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration receives olaparib/abiraterone/prednisone upon relapse (32:15) Combining PARP inhibitors with other DNA repair inhibitors; insights on the PSMAddition trial (37:14) Case: A man in his mid 60s with metastatic prostate adenocarcinoma and a BRCA germline mutation receives niraparib/abiraterone/prednisone (43:17) Case: A man in his early 60s with mCRPC and CDK12 mutations receives talazoparib/enzalutamide (45:54) CME information and select publications

We're going to cure cancer in our lifetime." It's a rallying cry at every charity event, every fundraiser, every race. But what does that actually mean?Dr. Sonal Gandhi, a medical oncologist, joins Ditch the Labcoat to break down what most people don't understand: we already cure cancer. All the time. Early stage cancers like breast, colon, and skin cancer caught in time have cure rates approaching 90 to 100 percent.The challenge is stage four cancer. Metastatic disease. Cancer that has spread to other organs. And even there, the conversation is shifting. Cancer is increasingly becoming a chronic illness. People are living longer with it, sometimes dying with it rather than from it, just like they do with heart disease or diabetes.Dr. Gandhi walks through what "curing cancer" really means, how treatment has evolved beyond chemotherapy into targeted therapies and immunotherapy, and why prevention matters. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, lack of exercise. But even doing everything right doesn't guarantee you won't get cancer. Age is the number one risk factor, and we can't modify that.She also challenges the guilt people carry when they're diagnosed and reframes the fear around the "C word." Maybe it's time to pull cancer back into the middle with the menu of other chronic illnesses we manage, not cure.If you've ever wondered what "curing cancer" actually means, why some cancers are more treatable than others, or what you can do to reduce your risk, this episode will reframe how you think about one of medicine's most feared diagnoses.If you've ever wondered why so many people have unexplained symptoms, why standard treatments fail them, or what actually works when medicine runs out of answers, this episode will reframe how you see chronic illness.Dr. Sonal Gandhi's LinkedinEpisode Takeaways1. We already cure cancer. Early stage cancers (stage 1 or 2) caught in time have cure rates approaching 90 to 100 percent, depending on the type.2. Cancer is not one disease. It's dozens of diseases with different stages, treatments, and outcomes. We're better at treating some than others.3. Stage four (metastatic) cancer is increasingly becoming a chronic illness. Treatments help people live longer with cancer, sometimes dying with it rather than from it.4. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, and lack of exercise. Being a healthy weight matters for cancer prevention.5. Age is the number one risk factor for cancer. Every decade you get older, cells get worse at repairing mistakes. We can't modify aging.6. Only 10 to 20 percent of cancers are due to inherited genes. Most cancers happen because of the complicated interplay between lifestyle, environment, and cellular aging.7. Immunotherapy works by preventing cancer cells from turning off the immune system, but it can cause severe autoimmune side effects that need rapid treatment.8. Whole body scans and experimental blood tests sound appealing, but they often create more harm than good. Screening needs to be done in context with clear downstream action plans.Episode Timestamps03:51 – What Does "Curing Cancer" Actually Mean?08:15 – Early Stage vs. Late Stage Cancer: The Critical Difference12:42 – How Chemotherapy, Targeted Therapy, and Immunotherapy Work18:35 – Prevention: Lifestyle Factors That Reduce Cancer Risk21:50 – Why Immunotherapy Can Cause Severe Side Effects30:48 – Cancer as a Chronic Illness, Not a Death Sentence38:22 – Environmental and Occupational Cancer Risks45:51 – Why Whole Body Scans Aren't the AnswerDISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (soundsdebatable.com) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University.

While menopause is often associated with aging, many women facing breast cancer experience it suddenly and much earlier than expected—bringing a wave of physical and emotional changes. From managing intense symptoms to confronting fears about future family-building, the journey can feel overwhelming. On today's episode, we are joined by Melody Johnson, a nurse practitioner who specializes in caring for women navigating these exact challenges. She will help us understand how treatment-induced menopause differs from natural menopause and the strategies available to cope with side effects while already carrying so much. We'll also take a closer look at fertility—an especially emotional and complex issue for younger women diagnosed before they've had the chance to start or grow their families. Whether you're newly diagnosed, supporting someone who is, or simply want to better understand this critical aspect of women's health, this conversation is here to inform, support, and remind you: you are not alone on this journey. What You'll Learn: • The difference between treatment-induced and age-related menopause • Common symptoms and why they can feel more severe during cancer treatment • How to manage menopause side effects alongside a breast cancer diagnosis • Fertility preservation options, including egg freezing and when to consider them • Why self-advocacy is critical when discussing fertility with your care team Chapters: 00:00 Introduction to treatment-induced menopause 01:29 Melody Johnson's background in oncofertility 02:45 What to expect from menopause symptoms 05:05 Key differences between induced and natural menopause 06:24 Managing symptoms during treatment 08:29 Fertility concerns for younger women 10:25 Is treatment-induced menopause permanent? 11:53 Questions to ask your doctor 13:24 Why these conversations matter 14:48 Final advice for women navigating fertility after diagnosis Learn more at komen.org and realpink.komen.org BreastCancer #Fertility #Menopause #WomensHealth #Oncofertility #CancerSupport #ReproductiveHealth #RealPink Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes. Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions. Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors. Key topics covered in this episode: The significance of NGS testing and PD-L1 scores in treatment decisions The role of chemotherapy in high PD-L1 patients Insights on dual checkpoint inhibitors based on recent clinical trials The latest options for KRAS G12C mutations and C-MET overexpression Practical considerations for managing treatment-related side effects Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology. Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care! #MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

Today's conversation is one that so many mothers will feel deep in their bones because it talks about what happens when life asks you to be the one who needs care. Our guest today has lived that shift in a profound way. In the midst of raising her young children, navigating the everyday chaos and fiercely advocating for her youngest daughter, Nylah, who was born with congenital heart disease, Nisha Jaime was suddenly diagnosed with breast cancer. There is an emotional whiplash to being the strong one for your child and then suddenly needing that same strength for yourself. Nisha will talk to us about what that was like and how she balanced it all with the help of her village. We'll talk about the ongoing realities of survivorship, including things like scanxiety and continued care and how her children are involved in her journey. Most importantly, we'll hear how she has turned her experience into support for other mothers walking a similar path and why that mission matters so deeply to her.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of metastatic urothelial carcinoma management, contrasting historical standards with the rapidly evolving frontline paradigm. As the field transitions into a new era of care, Drs Armstrong and Tawagi emphasized the importance of understanding trial data and toxicity management for both board preparation and clinical practice.The discussion began with details about the historical treatment paradigm, which relied on platinum-based chemotherapy followed by maintenance avelumab for patients who did not progress. However, the experts noted that the current SOC has shifted dramatically following findings from the landmark EV-302 trial, which evaluated the combination of enfortumab vedotin and pembrolizumab.They also explained that the toxicities associated with enfortumab vedotin plus pembrolizumab are highly testable and clinically relevant. Key adverse effects include skin toxicity and peripheral neuropathy, they said. Additionally, the hosts highlighted hyperglycemia and the risk of diabetic ketoacidosis, and emphasized that ocular toxicities, specifically dry eyes, also necessitate referrals to ophthalmology.In the second-line setting following enfortumab vedotin plus pembrolizumab, Drs Armstrong and Tawagi noted that the paradigm unclear, though treatment options include platinum-based chemotherapy or targeted agents. They recommended testing for FGFR mutations to determine patient eligibility for erdafitinib, as well as testing for HER2 expression to determine eligibility for trastuzumab deruxtecan.They also reported that for localized high-grade upper tract urothelial carcinoma, treatment options include neoadjuvant split-dose gemcitabine/cisplatin or upfront surgery followed by adjuvant chemotherapy. In the metastatic setting, they noted that rare disease variants like small cell carcinoma are treated with platinum doublets and immunotherapy, whereas adenocarcinoma management may require FOLFOX.

Today's episode is focusing on what you need to know regarding metastatic bladder cancer, with 2026 updates. This will include the need to know treatment options and toxicities for metastatic urothelial carcinoma, and also discuss the management of upper tract + variant non-urothelial histology.

Daraxonrasib, a first-in-class oral RAS inhibitor, nearly doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer, representing a potentially landmark advance in a historically difficult-to-treat disease. The antibody-drug conjugate datopotamab deruxtecan significantly improved progression-free and overall survival over chemotherapy in first-line triple-negative breast cancer, particularly for patients ineligible for immunotherapy. A Cochrane review of nearly 20,000 patients found anti-amyloid Alzheimer's therapies offer minimal clinically meaningful cognitive benefit while carrying meaningful safety risks, complicating their real-world use.

What does it take to turn the most terrifying moment of your life into a movement? For Yvonne McLean Florence, it started with discovering a lump she acted on right away. Yvonne is a HER2-positive breast cancer survivor, ordained minister, Worship in Pink Ambassador, former founder of Sisters R Us Circle of Survivors (SRUCOS) and is currently the reigning Ms. Pennsylvania Senior America 2025. But before all of that, she was a wife, a mother, a grandmother — and suddenly, a patient. In this powerful episode of Real Pink, Yvonne joins host Adam Walker to talk about what it felt like to receive a life-changing diagnosis, how her faith in God, family and friends carried her through chemotherapy and Herceptin infusions, and why she didn't stop when treatment ended. She'll share how she's bringing the conversation about breast health into churches across Philadelphia through Worship in Pink, what it means to build a Cancer Survivorship Resource Nook inside a congregation, and why she would like every survivor to discover how they can also reach back. This episode is part of our Health Equity Revolution series, which lifts up the voices, stories and solutions of the communities most impacted by breast cancer disparities.

People who had radiation treatment to the chest area for certain types of cancer early in life have an increased risk of breast cancer later in life. Today, we welcome a special guest back to the show, Amy Colver. Amy is Manager of Health Information & Publications at Komen and an oncology certified, licensed independent social worker who has worked in the oncology space, so she knows more about cancer from an educational standpoint than most. Today, she is here to share that she's also a cancer survivor and lives with the reality that a treatment she had for lymphoma in young adulthood put her at a higher risk of breast cancer. She'll talk to us about how to process risk and what ongoing care, screening and emotional resilience really looks like. Above all, Amy knows the power of turning awareness into action, and how understanding your risk factors can become more of a source of empowerment than fear.

She was 29 years old. No family history. No warning signs. She found it herself in the shower — and it changed everything. Claire was diagnosed with breast cancer at 29, went through a lumpectomy, chemotherapy, radiation, and eight years on and off Tamoxifen — all while teaching first grade, freezing her eggs, getting married, and becoming a mom to three kids. She lived 11 and a half years of clear scans and a full, beautiful life. Then last Christmas Eve, it came back. Stage 4. Metastatic. Liver and bones. And Claire's response? "It's just a little road bump." This episode is one of the most honest, funny, and genuinely hopeful conversations about metastatic breast cancer you will ever hear. Claire is the host of Perky Bits — a blog and podcast she started in 2014 to document her journey in real time — and she holds absolutely nothing back. What we cover: Finding a golf ball-sized tumor in the shower at 29 — and what happened next How Claire worked as a first grade teacher throughout chemo and radiation Why she froze her eggs before starting chemotherapy — and had three healthy children The GI symptoms that started in July 2024 that nobody connected to cancer for months — and the critical warning signs metastatic survivors need to know Getting the call on Christmas Eve that it had spread to her liver and bones What it actually feels like when treatment starts working — and her tumors start shrinking How she talks to her young kids about her treatment without terrifying them The connection between stress and recurrence — and what she wishes she'd managed differently Why stage 4 is not what it used to be — and the women thriving 15+ years out The unexpected blessings cancer gave her — including the line she ends every speaking engagement with: "Thank you, cancer." Where Perky Bits came from — and the story of the older gentleman who had to hold her breast with gauze for an hour post-biopsy (you can't make this stuff up) Important message for every survivor: Claire's metastatic diagnosis showed up as GI symptoms — bloating, distension, constipation, diarrhea — not a breast lump. Your mammograms matter. But so does listening to your body everywhere else. Connect with Claire:https://www.instagram.com/claireperkybits/ Listen to Perkybits here: https://podcasts.apple.com/us/podcast/perkybits-riding-the-waves-of-life-intro/id1890866013?i=1000759385674 Connect with Jen: Community: Not Today Cancer — The Inner Circle GET BrocElite: Mara Labs supplements - Use code NotTodayCancer for 20% off Instagram: https://www.instagram.com/jendelvaux/ Email me: jen@jendelvaux.com